检索结果-南通市图书馆

Autograft mediated adoptive immunotherapy of cancer in the context of autologous stem cell transplantation

World Journal of Clinical Oncology 2010年第1期1卷 29-34页

作者： luis.f.porrata Svetomir N Markovic Division of Hematology Department of MedicineMayo Clinic College of Medicine200 First St.SWRochesterMN 55905United States

The infused stem cell autograft in autologous stem cell transplantation(ASCT)has been viewed mainly as hematologic rescue from the myelosuppressive side effect of conditioning ***,recent reports have shown that the immune effector cells collected at the same time as the stem cells can produce an autologous graft-versus-tumor effect,similar to the graft-versus-tumor effect seen in allogeneic stem cell transplantation without the detrimental effects of graftversus-host *** this article,we review the different immune effector cells collected and infused from the stem cell autograft and their association with clinical outcome post-ASCT,suggesting that ASCT can be viewed not only as a therapeutic maneuver to recover bone marrow function after deliver high-dose chemotherapy,but also as an adoptive immunotherapeutic intervention capable of eradicating residual tumor cells in patients with cancer.

关键词： Adoptive immunotherapy Autologous graft versus tumor effect Autograft

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Autologous lymphocytes infusion

引用

World Journal of Hematology 2013年第2期2卷 59-61页

作者： luis.f.porrata Svetomir N Markovic Division of Hematology Department of Medicine Mayo Clinic Rochester MN 55905 United States

The graft vs tumor effect produced by the infusion of allo-reactive lymphocytes is considered to be the main mechanism of action in the eradication of tumor cells only reported in allogeneic stem cell transplantation. We present a case of a lymphoma patient infused with his collected bystander lymphocytes from is stem cell autograft after failing to collect enough stem cells to proceed with autologous stem cells transplantation, resulting in tumor response with no treatment related toxicity. This case illustrates the concept of autologous lymphocyte infusion, suggesting the possibility of an autograft vs tumor effect, as an effort to parallel donor lymphocyte infusion in allogeneic stem cell transplantation to create a graft vs tumor effect by increasing donor lymphocytes in the patient.

关键词： Autologous lymphocytes infusion Autograft vs tumor effect Natural killer cells Tumor regression Survival

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Day 100 Absolute Monocyte/Lymphocyte Prognostic Score and Survival Post Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation in Diffuse Large B-Cell Lymphoma

引用

Journal of Cancer Therapy 2013年第8期4卷 1298-1305页

作者： Ana I. Velazquez David J. Inwards Stephen M. Ansell Ivana N. Micallef Patrick B. Johnston William J. Hogan Svetomir N. Markovic luis f. porrata Division of Hematology Department of Internal Medicine Mayo Clinic Rochester USA

Day 100 prognostic factors post-autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) to predict clinical outcomes in diffuse large B-cell lymphoma (DLBCL) patients have not been studied. Thus, we retrospectively examined if day 100 absolute monocyte/lymphocyte prognostic score (AMLPS-100) affects clinical outcomes by landmark analysis from day 100 post-APBHSCT in DLBCL. Only DLBCL patients in complete remission at day 100 post-APBHSCT were evaluated. from 2000 to 2007, 134 consecutive DLBCL patients are qualified for the study. Patients with a day 100 absolute monocyte count (AMC-100) ≥ 630 cells/μL and day 100 absolute lymphocyte count (ALC-100) ≤ 1000 cells/μL experienced inferior overall survival (OS) and progression free survival (PfS). On multivariate analysis, the AMC-100 and ALC-100 remained independent predictors of OS and PfS. Combining both values into the AMLPS-100, the 5-year OS rates for low, intermediate, and high AMLPS-100 risk groups were 94% (95% CI, 83.0% - 98.1%), 70% (95% CI, 58.6% - 80.1%), and 13% (95% CI, 3.4% - 40.5%), respectively;and the 5-year PfS rates were 87% (95% CI, 74.0% - 94.1%), 68% (95% CI, 56.0% - 77.8%), and 13% (95% CI, 3.4% - 40.5%), respectively. The AMLPS-100 is a simple biomarker score that can stratify clinical outcomes from day 100 post-APBHSCT in DLBCL patients.

关键词： Monocyte/Lymphocyte Prognostic Score Diffuse Large B-Cell Lymphoma Survival Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Absolute Lymphocyte/Monocyte Ratio at Diagnosis and Interim Positron-Emission Tomography Predict Survival in Classical Hodgkin Lymphoma

引用

Journal of Cancer Therapy 2013年第3期4卷 452-459页

作者： luis f. porrata Kay M. Ristow Thomas M. Habermann Thomas E. Witzig Joseph P. Colgan David J. Inwards Stephen M. Ansell Ivana N. Micallef Patrick B. Johnston Grzegorz Nowakowski Carrie A. Thompson Svetomir N. Markovic Division of Hematology Internal Medicine Mayo College of Medicine Rochester USA

Interim Positron-Emission Tomography (int-PET) and the peripheral blood absolute lymphocyte/monocyte ratio at di- agnosis (ALC/AMC-DX) have been shown to be predictors for progression-free survival (PfS) and time to progression (TTP) in classical Hodgkin lymphoma (cHL). Therefore, we studied if the combination of ALC/AMC-DX and the (int-PET) can further stratified PfS and TTP in cHL patients. Patients were required to be diagnosed, treated, and followed with int-PET at Mayo Clinic, Rochester, Minnesota. from 2000 until 2008, 111 cHL patients qualified for the study. The median follow-up was 2.8 years (range: 0.3 - 10.4 years). Patients with a negative int-PET (N = 98) pre- sented with a higher ALC/AMC-DX (median of 2.32, range: 0.26 - 37.5) compared with patients with a positive int-PET (N = 13) (median of 0.9, range: 0.29 - 3.10), p 1.1. Group 1 experienced superior PfS and TTP in comparison with the other groups. In conclusion, the combination of ALC/AMC-DX and the int-PET provides a simple model to assess clinical outcomes in cHL.

关键词： Classical Hodgkin Lymphoma Absolute Lymphocyte/Monocyte Ratio at Diagnosis Interim PET-Scan Progression-free Survival Time to Progression

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：